DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9b4tkk/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Advenchen Laboratories, LLC
- Ariad Pharmaceuticals, Inc.
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Celgene Corporation
- Immunomedics, Inc.
- Nerviano Medical Sciences S.r.l.
- Novartis AG
- ponatinib hydrochloride
- Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer
- Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer
For more information visit http://www.researchandmarkets.com/research/9b4tkk/medullary_thyroid